false
0001390478
0001390478
2025-10-01
2025-10-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): October 1, 2025
SELLAS
Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-33958 |
|
20-8099512 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
| |
|
7 Times Square, Suite 2503
New York, NY 10036 |
|
|
| |
|
(Address of Principal Executive
Offices) (Zip Code) |
|
|
| |
|
|
|
|
| Registrant’s
telephone number, including area code: (646) 200-5278 |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
symbol(s) |
Name of each exchange
on which registered |
| Common Stock, $0.0001 par value per share |
SLS |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
| Item 1.01 |
Entry into a Material Definitive Agreement. |
On October 1, 2025, SELLAS Life Sciences Group, Inc.
(the “Company”), as subtenant, entered into a Letter Agreement with Times Square Tower Associates LLC (the “Sublandlord”)
relating to a certain sublease (as amended) of certain premises located at Times Square Tower, 7 Times Square, New York, New York (the
“Sublease”). The Letter Agreement provides for the extension of the expiration date of the Sublease from September 30, 2026
to September 30, 2027. The annual rent remains unchanged.
The foregoing description of the Letter Agreement
is qualified in its entirety by reference to the Letter Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number |
|
Description |
| 10.1 |
|
Letter Agreement by and between SELLAS Life Sciences Group, Inc. and Times Square Tower Associates LLC |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
SELLAS Life Sciences Group, Inc. |
| |
|
|
|
| |
|
|
|
| Date: |
October 3, 2025 |
By: |
/s/ John T. Burns |
| |
|
|
Name: |
John T. Burns |
| |
|
|
Title: |
Senior Vice President, Chief Financial Officer |
